P.O. Box 134
Malvern, PA 19355
United States
610 725 1500
https://www.galeratx.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 7
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. J. Mel Sorensen M.D. | CEO, President & Director | 632,64k | N/D | 1957 |
Dr. Robert A. Beardsley M.B.A., Ph.D. | Co-Founder & COO | 464,59k | N/D | 1962 |
Mr. Christopher Degnan | Chief Financial Officer | 474,05k | N/D | 1980 |
Ms. Jennifer Evans Stacey Esq. | Chief Legal & Compliance Officer and Secretary | N/D | N/D | 1965 |
Ms. Andie Collier | Chief Regulatory & Quality Affairs Officer | N/D | N/D | N/D |
Ms. Judy Schnyder | Senior Vice President of Clinical Operations & Data Management | N/D | N/D | N/D |
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
L'ISS Governance QualityScore di Galera Therapeutics, Inc. al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 8; diritti degli azionisti: 7; retribuzione: 8.